Results 241 to 250 of about 9,647,508 (315)

Parabiosis, Assembloids, Organoids (PAO)

Advanced Science, EarlyView.
This review evaluates parabiosis, organoids, and assembloids as complementary disease models spanning systemic, organ, and multi‐organ levels. It highlights their construction strategies, applications, and current limitations, while emphasizing their integration with frontier technologies such as artificial intelligence, organ‐on‐a‐chip, CRISPR, and ...
Yang Hong, Lavonda Li, Lijie Yan, Long Bai, Jiacan Su, Xingcai Zhang   +5 more
wiley   +1 more source

Parkinson's Disease in Australia: Evaluation of Regional Differences and Health-Related Quality of Life. [PDF]

Aust J Rural Health
Messing A, Hobbs MJ, Quirk F, Apthorp D.
europepmc   +1 more source

PACS‐2 Mitigates NPSC Apoptosis and Intervertebral Disc Degeneration by Preserving MAM Integrity via the SP1/LRRK2/Mfn2 Axis

Advanced Science, EarlyView.
This study investigates the role of PACS‐2 in IDD, demonstrating that it suppresses the nuclear translocation of SP1, thereby downregulating its downstream target LRRK2. This reduces LRRK2‐mediated ubiquitination and degradation of Mfn2 through the JNK pathway, preserving MAM integrity and promoting NPSC survival.
Liang Kang, Jiaqi Wang, Chenhao Zhao, Qiuwei Li, Zhigang Zhang, Huaqing Zhang, Chongyu Jia, Luping Zhou, Yanxin Wang, Yu Chen, Kaixuan Li, Xu Yan, Jie Fang, Haibao Wang, Dandan Wang, Pingping Su, Jingyu Zhang, Zhiwei Chen, Renjie Zhang, Cailiang Shen   +19 more
wiley   +1 more source

Corrigendum: The Gut-Brain Axis in Parkinson's Disease. [PDF]

Cold Spring Harb Perspect Med
Gao V, Crawford CV, Burré J.
europepmc   +1 more source

Microglial Feimin Alleviates Cognitive Impairment in High‐Fat Diet‐Fed Mice

Advanced Science, EarlyView.
Microglial feimin deletion exacerbates lipotoxicity‐induced neuroinflammation and cognitive decline. In both in vitro and in vivo models, loss of feimin aggravated lipid droplet accumulation, IL‐1β/IL‐6 release, and neuronal injury through the PI3K–AKT–mTOR pathway, ultimately leading to severe neuronal apoptosis and cognitive impairment under high‐fat
Ran Gao, Zhonghua Xiong, Wenting Su, Jiahui Deng, Bin Zhai, Gaizhi Zhu, Min Zhang, Qi Zeng, Jinming Qiu, Ziqing Bian, He Xiao, Guoming Luan, Renxi Wang   +12 more
wiley   +1 more source

Exosomes as drug delivery vehicles for Parkinson's disease therapy.

Journal of Controlled Release, 2015
Matthew J. Haney, N. Klyachko, Yuling Zhao, Richa Gupta, E. Plotnikova, Zhijian He, Tejash T. Patel, A. Piroyan, Marina Sokolsky, A. Kabanov, E. Batrakova   +10 more
semanticscholar   +1 more source

Reply: "Navigating the Neuropsychiatric Risks of Foslevodopa/Foscarbidopa in Patients with Parkinson's Disease". [PDF]

Mov Disord Clin Pract
Hauw F, Méneret A, Mantisi L, Letrillart H, Grabli D, Brohée S, Roze E.   +6 more
europepmc   +1 more source

Advances in Drug Development for Parkinson's Disease: Present Status [PDF]

, 2014
Dibbanti HariKrishnaReddy, Shubham Misra, Bikash Medhi   +2 more
openalex   +1 more source

Olfactory‐to‐Entorhinal Network Dysrhythmias Drive Parkinson's Cognitive Impairment Through Frequency‐Specific Oscillatory Decoupling

Advanced Science, EarlyView.
Wang et al reveal that in the olfactory system, the selective impairment of gamma‐driven Barcode features underlying early olfactory deficits, while the selective impairment of theta‐driven Barcode features underlying later cognitive deficits, further establishing cross‐network gamma oscillations in the early stage as a biomarker of later cognitive ...
Shuaishuai Wang, Zhishen Cai, Xingfeng Mao, Yixuan Zhang, Yunlong Pan, Jiawen Cheng, Xuechun Wang, Hengyi Song, Sasaki Takuya, Ming Lu, Gang Hu, Xiuxiu Liu, Yingmei Lu, Feng Han   +13 more
wiley   +1 more source

Public Healthcare for People with Parkinson's Disease in Portugal: Rising to the Challenge. [PDF]

Mov Disord
Varanda S, Carneiro G, Pinho J.
europepmc   +1 more source